Specific Biologics raises $35 million for ALS gene editing
Specific Biologics raised $35 million to move a C9ORF72-linked ALS gene-editing candidate into an adaptive Phase I/II trial, backed by an expanded investor syndicate.
Topic
Gene Editing
Topic
Gene Editing
DropGenie Lands $5M Seed+ to Scale Gene-Editing in Scarce Patient Cells
DropGenie raised $5M in Seed+ funding from BDC Thrive, Skeleton Key, Merck's GHI Fund and others to scale a gene-editing platform…
Palmer Luckey and Ben Lamm Launch Warhound With $200 Million
Palmer Luckey and Ben Lamm's new startup Warhound raised $200 million to clone and gene-edit military dogs, with the first modifi…
Warhound Raises $200M Seed at $1.2B Valuation to Clone Military Dogs
Warhound exited stealth October 22 with $200M in seed funding at a $1.2B valuation. Backers include Sequoia, In-Q-Tel and Lux Cap…
Warhound Exits Stealth With $200 Million to Clone US Military Dogs
Ben Lamm and Palmer Luckey's Warhound launches with $200M to clone and gene-edit US military dogs, replacing an 80%-European supp…
Epicrispr Biotechnologies Lands $8M Grant
Epicrispr Biotechnologies has received an $8 million grant, FinSMEs reports. The non-dilutive award adds capital to the epigenomi…
Beam Therapeutics Sues Chinese Biotech Over Alleged IP Theft
Beam Therapeutics has filed suit against a Chinese biotech and a VC-backed startup, alleging theft of intellectual property tied…
Scribe Raises $129 Million in Rare Gene Editing IPO
Scribe raised $129 million in a gene editing IPO that stands out in a biotech market where new listings have become rare, BioPhar…